Patents by Inventor Joshua E. Scharff

Joshua E. Scharff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOTOXIN WITH IN VIVO T CELL SUPPRESSANT ACTIVITY AND METHODS OF USE
    Publication number: 20030157093
    Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
    Type: Application
    Filed: September 3, 1999
    Publication date: August 21, 2003
    Inventors: DAVID M. NEVILLE, JR., JOSHUA E. SCHARFF, JERRY TODD THOMPSON, HUAIZHONG HU, SHENGLIN MA
  • Immunotoxin with in vivo T cell suppressant activity and methods of use
    Patent number: 5725857
    Abstract: In one embodiment, the invention provides a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-CRM9 conjugate which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In another embodiment, the invention provides an anti-V.beta.-CRM9 immunoconjugate. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-CRM9 conjugate which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: March 10, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Neville, Joshua E. Scharff
  • Immunotoxin with in-vivo T cell suppressant activity
    Patent number: 5167956
    Abstract: The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias and lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.
    Type: Grant
    Filed: February 11, 1991
    Date of Patent: December 1, 1992
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David M. Neville, Jr., Joshua E. Scharff